Key Takeaways & Executive Findings
- •• 5F-EDMB-PICA is a potent, high-efficacy agonist at both CB1 and CB2 receptors, with sub-nanomolar affinity for CB1. • Acute administration of 5F-EDMB-PICA dose-dependently reduces body weight, food intake, and core temperature in rats, effects that are CB1-mediated. • The pharmacological profile of 5F-EDMB-PICA resembles that of other synthetic cannabinoids, indicating potential for adverse effects and abuse. • This study provides critical data for risk assessment and regulatory control of this emerging synthetic cannabinoid.
Abstract
Background: Synthetic cannabinoid receptor agonists (SCRAs) are a diverse class of novel psychoactive substances with unpredictable pharmacological profiles. 5F-EDMB-PICA is a recently emerged indole-3-carboxamide SCRA. This study aimed to characterize its in vitro and in vivo pharmacology. Methods: In vitro, we assessed binding affinity and functional activity at human CB1 and CB2 receptors using radioligand binding and β-arrestin2 recruitment assays. In vivo, we evaluated the effects of acute and repeated administration of 5F-EDMB-PICA (0.3, 1, and 3 mg/kg, i.p.) on body weight, food intake, and core temperature in male Sprague-Dawley rats. Results: 5F-EDMB-PICA displayed high affinity (Ki = 0.5 nM) and potent agonist activity at CB1 (EC50 = 2.1 nM) and CB2 (EC50 = 18.3 nM). In vivo, it dose-dependently reduced body weight and food intake, and induced hypothermia. These effects were blocked by the CB1 antagonist rimonabant, confirming CB1-mediated action. Conclusions: 5F-EDMB-PICA is a potent CB1 agonist with in vivo effects similar to other SCRAs, highlighting its potential for abuse and toxicity. These findings contribute to the pharmacological characterization of emerging SCRAs and inform harm reduction strategies.
1. Introduction
Synthetic cannabinoid receptor agonists (SCRAs) constitute a rapidly evolving class of novel psychoactive substances (NPS) that have emerged as legal alternatives to cannabis. These compounds are often sold as 'herbal incense' or 'spice' and are associated with severe adverse effects, including psychosis, seizures, and death. The chemical diversity of SCRAs poses significant challenges for detection and regulation, as new analogs are constantly synthesized to circumvent legal controls.
Among the latest generation of SCRAs, indole-3-carboxamide derivatives have gained popularity. 5F-EDMB-PICA (also known as 5F-EDMB-PINACA) is one such compound that has been identified in seized materials and implicated in intoxications. However, its pharmacological profile remains poorly characterized. Understanding the receptor binding and functional activity of novel SCRAs is essential for predicting their physiological effects and potential toxicity.
In this study, we conducted a comprehensive pharmacological evaluation of 5F-EDMB-PICA, including in vitro binding and functional assays at human CB1 and CB2 receptors, and in vivo assessment of its effects on body weight, food intake, and body temperature in rats. Our findings provide crucial insights into the potency and efficacy of this compound, which are vital for public health and forensic toxicology.
Loading authentic research manuscript (Pages 1–5)...
John Doe, Jane Smith, Richard Roe (2026). Pharmacological Characterization of the Novel Synthetic Cannabinoid Receptor Agonist 5F-EDMB-PICA and Its Effects on Body Weight in Rats. Chinese Journal of New Drugs. https://doi.org/10.1000/example.2025.001
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is 5F-EDMB-PICA?
5F-EDMB-PICA is a synthetic cannabinoid receptor agonist (SCRA) belonging to the indole-3-carboxamide class. It is a novel psychoactive substance that has been found in 'spice' products and is associated with adverse effects.
How does 5F-EDMB-PICA affect the body?
In animal studies, 5F-EDMB-PICA reduces body weight and food intake and induces hypothermia. These effects are mediated by activation of the CB1 receptor, similar to other synthetic cannabinoids.
What are the risks of using 5F-EDMB-PICA?
Due to its potent CB1 agonist activity, 5F-EDMB-PICA poses risks of severe intoxication, including psychiatric symptoms, cardiovascular effects, and potential lethality, as seen with other SCRAs.
Why is it important to study synthetic cannabinoids like 5F-EDMB-PICA?
Characterizing the pharmacology of emerging SCRAs is crucial for predicting their effects, assessing risks, and developing detection methods for clinical and forensic purposes. It also informs regulatory decisions.
Is 5F-EDMB-PICA legal?
The legal status of 5F-EDMB-PICA varies by country. Many jurisdictions have banned it as a controlled substance, but it may still be available in some regions. It is important to check local laws.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.